The prevention and treatment of missing data in clinical trials: an FDA perspective on the importance of dealing with it.
about
The current practice of handling and reporting missing outcome data in eight widely used PROMs in RCT publications: a review of the current literatureStrategies for dealing with missing data in clinical trials: from design to analysisReporting missing participant data in randomised trials: systematic survey of the methodological literature and a proposed guideThe prevention and treatment of missing data in clinical trialsThe prevention and handling of the missing dataProper analysis in clinical trials: how to report and adjust for missing outcome data.Transparent reporting of missing outcome data in clinical trials: applying the general principles of CONSORT 2010.Handling missing data in a duloxetine population pharmacokinetic/pharmacodynamic model - imputation methods and selection models.Sensitivity analyses for partially observed recurrent event data.A regulatory perspective on missing data in the aftermath of the NRC report.A novel complete-case analysis to determine statistical significance between treatments in an intention-to-treat population of randomized clinical trials involving missing data.A systematic review of randomised controlled trials in rheumatoid arthritis: the reporting and handling of missing data in composite outcomes.Choosing estimands in clinical trials with missing data.Missing data frequency and correlates in two randomized surgical trials for urinary incontinence in women.Fallacies of last observation carried forward analyses.Volunteer bias in recruitment, retention, and blood sample donation in a randomised controlled trial involving mothers and their children at six months and two years: a longitudinal analysis.The hospital outpatient alcohol project (HOAP): protocol for an individually randomized, parallel-group superiority trial of electronic alcohol screening and brief intervention versus screening alone for unhealthy alcohol useCardiovascular outcome studies with novel antidiabetes agents: scientific and operational considerationsAdvances in clinical trials for movement disorders.Identifying research priorities for effective retention strategies in clinical trials.Switch to Abobotulinum toxin A may be useful in the treatment of neurogenic detrusor overactivity when intradetrusor injections of Onabotulinum toxin A failed.Proportion and characteristics of men with unknown risk category in the National Prostate Cancer Register of Sweden.Ocular blood flow in glaucoma - the Leuven Eye Study.Missing CD4+ cell response in randomized clinical trials of maraviroc and dolutegravir.Choice of estimand and analysis methods in diabetes trials with rescue medication.Establishing Good Practices for Exposure-Response Analysis of Clinical Endpoints in Drug Development.Model-based dose finding under model uncertainty using general parametric models.Good intentions and ICH-GCP: Trial conduct training needs to go beyond the ICH-GCP document and include the intention-to-treat principle.The challenges of improving statistical practice in alcohol treatment research.Estimands in clinical trials - broadening the perspective.A systematic review and development of a classification framework for factors associated with missing patient-reported outcome data.Effect of intrathecal baclofen bolus injection on ankle muscle activation during gait in patients with acquired brain injury.New polymorphisms associated with response to anti-TNF drugs in patients with moderate-to-severe plaque psoriasis.Quantitative investigation of inappropriate regression model construction and the importance of medical statistics experts in observational medical research: a cross-sectional study.Long term extension of a randomised controlled trial of probiotics using electronic health records.
P2860
Q26773044-2196CD58-7C9F-4AD6-9B49-2FD02E43E1A1Q26999795-FC787E76-77ED-47FB-9A45-1640E093193CQ28076913-BC73C0A4-69D7-4466-AE3B-A9183585C0E1Q30571921-19529C89-A39E-44EB-ACDC-2B1745F33480Q30641920-8DBA6D3D-BABB-400A-9320-003DDE7C54BFQ30646667-ECF9933E-1C61-4B1C-9990-87B5242ADFF9Q30811010-8886FAA7-B732-44CE-A7B7-819761187337Q30813682-A5BB30A4-C087-4A90-926D-2AD5A02E11DEQ31018361-8772196A-3EB1-48F6-A092-44B7F496C760Q31032578-CE6A193C-A735-4503-B150-333F467DEAB1Q31102708-A612399D-8F5C-4263-A79F-69F503B54D97Q31105054-A2017C54-0955-4331-BCBE-D78936789B9CQ31119719-EA482425-629B-45D0-9DBD-D345EE203024Q35584725-6E8BD540-0DB8-43C5-83CA-7BBF94C0C3CFQ36669613-9E52D251-5E4A-4241-8C01-058102224100Q36996957-F6728EA3-CD2C-49AC-ABBE-E20627427E02Q37155064-329CC10B-0C6A-46E4-B3A7-2B99D363D5B1Q37577148-3501806D-AAFC-4C47-9441-629AF932ECC4Q38573937-AB3E1270-9BD8-4F71-BC38-672618A5BB15Q38599438-74FF677C-74F3-4B7E-834C-74BF8CFF3F19Q38826378-7541EE6F-10B9-4702-88A9-508FD3531F62Q39282641-103219FA-ABC1-427F-8563-E7C95A1214E5Q39983662-1BC1A3A1-0AFC-477F-BA5F-4F4A8C44E209Q40544015-02C926C7-1EB1-47F1-BDBE-8C8EC05C9374Q40576360-8E6CE6A2-4AB5-4782-8C68-5B7A481BC366Q41819996-457353A0-3972-4C9E-A4C5-45501EA76C36Q43889519-36F2CBCE-9811-4ABF-925F-CA4A5A37E70CQ45099696-C728ECD1-A9AA-4D81-95DE-CE1491F81E15Q45979815-77541884-4C7C-4134-B415-DFD6689C9697Q47411811-03160540-2060-4433-8A25-13E506EF7A2FQ47619222-70100B3E-2064-42A5-991D-66D294680490Q48788653-5A6517C8-4955-4C3D-B52D-B8EAC41784ECQ50228159-B6AF0A80-C745-46A3-B8A8-A7164EEBC332Q55038848-7B44C5F1-913D-4021-98AC-15ED678EF51AQ55375164-DBA064F2-EF12-40F2-910B-C87BE2BA1F7F
P2860
The prevention and treatment of missing data in clinical trials: an FDA perspective on the importance of dealing with it.
description
2012 nî lūn-bûn
@nan
2012 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2012 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
name
The prevention and treatment o ...... importance of dealing with it.
@ast
The prevention and treatment o ...... importance of dealing with it.
@en
The prevention and treatment o ...... importance of dealing with it.
@nl
type
label
The prevention and treatment o ...... importance of dealing with it.
@ast
The prevention and treatment o ...... importance of dealing with it.
@en
The prevention and treatment o ...... importance of dealing with it.
@nl
prefLabel
The prevention and treatment o ...... importance of dealing with it.
@ast
The prevention and treatment o ...... importance of dealing with it.
@en
The prevention and treatment o ...... importance of dealing with it.
@nl
P2860
P356
P1476
The prevention and treatment o ...... importance of dealing with it.
@en
P2093
P2860
P304
P356
10.1038/CLPT.2011.340
P407
P577
2012-02-08T00:00:00Z